Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sberbank will launch a platform for trading green energy certificates

10/12/23 SBER

Novatek increased gas exports by 38.4% in 9 months

10/12/23 NVTK

Moscow Exchange wants to return the T0 mode

10/12/23 MOEX

Harmony Biosciences bought Zynerba Pharmaceuticals

10/12/23 ZYNE

Novatek to sell gas pipeline to Murmansk to Gazprom

10/12/23 NVTK

Iraqi Ministry of Energy expects production at West Qurna-2 to increase by 60%

10/11/23 LKOH

Caterpillar announced a quarterly dividend

10/11/23 CAT

Aeroflot increased transportation by 4.7% in September

10/11/23 AFLT

ExxonMobil takes over Pioneer Natural Resources

10/11/23 PXD

Krasny Kotelshchik reported for 9 months of 2023 by RAS

10/11/23 KRKO